DrugDashboards

Ryaltris

olopatadine hydrochloride and mometasone furoate · OLOPATADINE HYDROCHLORIDE 665 ug/1; MOMETASONE FUROATE MONOHYDRATE 25 ug/1 · Spray, Metered · Nasal · Hikma Specialty Usa Inc.

NDC 59467-0700-27 · 12 CARTON in 1 BOX / 1 BOTTLE, SPRAY in 1 CARTON / 240 SPRAY, METERED in 1 BOTTLE, SPRAY · NDA · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately. The price has held steady around $7.67 per gram over the past year. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$7.67per GMinvoice-surveyed acquisition cost · Aug 19, 2026
  • Part D plans paid (avg)$8.34per dosage unitgross, before rebates — matched by drug name · 2024
  • Part D point of sale (median)$8.12per unitnegotiated price across 1,117 plans — before rebates · Apr 1, 2026
  • Federal ceiling (Big4)$185.29per package of 29GMHikma Specialty USA Inc. · Jan 1, 2026

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$8.12per unit
middle half $7.80$8.23 · 1,117 plans · Apr 1, 2026
Est. net of rebates
$4.87–$6.09
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
20%of plans cover it
tier 3 · prior auth 1% · step therapy 24% · qty limit 1%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

$0$5.00$10.00Apr 2023Sep 2026$7.67
30 price points · per GMSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$249.00
Reported to Texas DSHS · 2026 annual filing · Hikma Pharmaceuticals USA Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$1.4M
5,943 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

20Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • 2 active manufacturers+20

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for olopatadine hydrochloride and mometasone furoate (other) in the next 90 days

sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
NDA211746
TE code
Approval date
Jan 13, 2022
Patents / exclusivity
17 patents, 1 exclusivities
TypeNumber / codeExpires
exclusivityNPPJul 7, 2029
patent12653833Nov 21, 2044
patent12303635Apr 8, 2039
patent11679210Sep 3, 2038
patent11400101Sep 4, 2034
patent12064442Sep 4, 2034
patent10016443Sep 4, 2034
patent10517880Sep 4, 2034
patent9750754Sep 4, 2034
patent10765686Sep 4, 2034
patent10561672Sep 4, 2034
patent9370483Sep 4, 2034

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class II · OngoingSep 24, 2024
    Glenmark Pharmaceuticals Inc., USADefective Delivery System: The dip tube is clogged causing the spray not to work.

Manufacturers of olopatadine hydrochloride and mometasone furoate (Spray, Metered)

LabelerStrengthFirst seenLast seen
Glenmark Pharmaceuticals Inc., USAOLOPATADINE HYDROCHLORIDE 665 ug/1; MOMETASONE FUROATE MONOHYDRATE 25 ug/1Aug 26, 2026Sep 2, 2026
Hikma Specialty Usa Inc.OLOPATADINE HYDROCHLORIDE 665 ug/1; MOMETASONE FUROATE MONOHYDRATE 25 ug/1Aug 26, 2026Sep 2, 2026
Glenmark Pharmaceuticals Inc., USAOLOPATADINE HYDROCHLORIDE 25 ug/1; MOMETASONE FUROATE MONOHYDRATE 665 ug/1Jul 22, 2026Aug 19, 2026
Hikma Specialty Usa Inc.OLOPATADINE HYDROCHLORIDE 25 ug/1; MOMETASONE FUROATE MONOHYDRATE 665 ug/1Jul 22, 2026Aug 19, 2026
Glenmark Pharmaceuticals Inc., USAMOMETASONE FUROATE MONOHYDRATE 25 ug/1; OLOPATADINE HYDROCHLORIDE 665 ug/1Jul 15, 2026Jul 15, 2026
Hikma Specialty Usa Inc.MOMETASONE FUROATE MONOHYDRATE 25 ug/1; OLOPATADINE HYDROCHLORIDE 665 ug/1Jul 15, 2026Jul 15, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Ryaltris — NDC 59467-0700-27," retrieved September 3, 2026, https://drugdashboards.com/drug/59467070027.

Free to cite with attribution — see how the data is put together.